IBSA UK&I has announced the launch of Perovial, a treatment for the management of acute Peyronie’s disease (PD).

Kahimmune Therapeutics, a biotechnology company specialising in immuno-oncology, has entered an exclusive licensing agreement with Gustave Roussy and Société d’Accélération du Transfert de ...

ALK has announced that its EURneffy 1mg nasal adrenaline spray has received a positive opinion from the Committee for ...

En Carta Diagnostics, a start-up company developing molecular diagnostics kits, has announced that its EC Pocket Lyme test has received Breakthrough Device Designation from the US Food and Drug ...

ENA Respiratory has started dosing participants in its phase 2 community study of INNA‑051, a dry‑powder nasal spray designed to strengthen the body’s natural antiviral defences and reduce the impact ...

Akari Therapeutics has filed a new US provisional patent covering AKTX-102, its second antibody drug conjugate targeting ...

Gedeon Richter UK has assumed full marketing and distribution responsibilities for the neuropsychiatry medicine cariprazine ...

Corcept Therapeutics, a pharmaceutical company specialising in cortisol-modulating medications, has announced that its ...

The EC’s approval was based on results from the phase 3 OASIS-HAE study. The study showed that an 80mg dose of Dawnzera every ...

ErVimmune, a preclinical biotechnology company focused on the development of cell therapies and cancer vaccines, has ...

CERo has released new findings from its ongoing phase 1 CertainT‑1 study evaluating CER‑1236, a first‑in‑human chimeric ...

Argo Biopharma has announced that the first patient has been dosed in a global phase 2b clinical trial of BW‑20829, an siRNA therapy being evaluated in adults with elevated lipoprotein (a) and ...